News
-
-
PRESS RELEASE
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Lonza extends collaboration with major pharmaceutical partner for integrated commercial supply of antibody-drug conjugates, including construction of dedicated bioconjugation capacity in Visp, and commercial antibody manufacturing for new ADC therapy -
-
-
-
-
-
PRESS RELEASE
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza and Vertex sign a long-term commercial supply agreement for CASGEVY® cell therapy based on CRISPR/Cas9 gene-editing technology. Lonza to manufacture at Geleen, NL facility approved by FDA, EMA, and MHRA -
-
PRESS RELEASE
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
Lonza Group AG's wholly-owned Lonza Finance International NV prices dual-tranche EUR 1.2 billion straight bonds with 3.25% and 3.50% coupons for six and ten years respectively. Bonds to be listed on Luxembourg Stock Exchange for general corporate purposes
